Download PDF
Semin Reprod Med 2008; 26(1): 022-034
DOI: 10.1055/s-2007-992921
© Thieme Medical Publishers

Polycystic ovary syndrome in the Indian Subcontinent

Gautam N. Allahbadia1 , 2 , Rubina Merchant2
  • 1The Prince Aly Khan Hospital IVF Center and The Aesculap Academy-Asia, Pacific Center For Minimally Invasive Surgery, Training & Research, Mazgaon, Mumbai, India
  • 2Rotunda - The Center For Human Reproduction, Bandra, India
Further Information

Publication History

Publication Date:
08 January 2008 (online)

    Permissions and Reprints

ABSTRACT

Polycystic ovary syndrome (PCOS) is a complex, multifaceted, heterogeneous disorder that affects ~5 to 10% of women of reproductive age. It is characterized by hyperandrogenism, polycystic ovaries, and chronic anovulation along with insulin resistance, hyperinsulinemia, abdominal obesity, hypertension, and dyslipidemia as frequent metabolic traits (metabolic syndrome) that culminate in serious long-term consequences such as type 2 diabetes mellitus, endometrial hyperplasia, and coronary artery disease. It is one of the most common causes of anovulatory infertility. However, the heterogeneous clinical features of PCOS may change throughout the life span, starting from adolescence to postmenopausal age, largely influenced by obesity and metabolic alterations, and the phenotype of women with PCOS is variable, depending on the ethnic background.

The etiology of PCOS is yet to be elucidated; however, it is believed that in utero fetal programming may have a significant role in the development of PCOS phenotype in adult life. Though a woman may be genetically predisposed to developing PCOS, it is only the interaction of environmental factors (obesity) with the genetic factors that results in the characteristic metabolic and menstrual disturbances and the final expression of the PCOS phenotype.

Irrespective of geographic locations, a rapidly increasing prevalence of polycystic ovarian insulin resistance syndrome, excess body fat, adverse body fat patterning, hypertriglyceridemia, and obesity-related disease, such as diabetes and cardiovascular disease, have been reported in Asian Indians, suggesting that primary prevention strategies should be initiated early in this ethnic group. In lieu of the epidemic increase in the prevalence of obesity and diabetes mellitus in most industrialized countries including China and India owing to Westernization, urbanization, and mechanization, and evidence suggesting a pathogenetic role of obesity in the development of PCOS and related infertility, active intervention to combat the malice of these disorders is warranted. Pharmacologic therapy is a critical step in the management of patients with metabolic syndrome when lifestyle modifications fail to achieve the therapeutic goals, and studies in China and India have proved to be effective.

KEYWORDS

Polycystic ovary syndrome - Indian subcontinent - ethnicity - Asian Indians - India

REFERENCES

  • 1 Sheikhha M H, Kalantar S M. Diagnostic criteria in polycystic ovary syndrome. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 27-32
    Google Scholar
  • 2 Balen A H, Dunger D. Pubertal maturation of the internal genitalia.  Ultrasound Obstet Gynecol. 1995;  6 164-165
    PubMedGoogle Scholar
  • 3 Elting M W, Korsen T JM, Rekers-Mombarg L TM, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing.  Hum Reprod. 2000;  15 24-28
    CrossrefPubMedGoogle Scholar
  • 4 Zawadzki J A, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR Polycystic Ovary Syndrome. Boston, MA; Blackwell Scientific 1992: 377-384
    Google Scholar
  • 5 Polson D W, Adams J, Wadsworth J, Franks S. Polycystic ovaries - a common finding in normal women.  Lancet. 1988;  1 870-872
    PubMedGoogle Scholar
  • 6 Rodin D A, Bano G, Bland J M, Taylor K, Nussey S S. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women.  Clin Endocrinol (Oxf). 1998;  49 91-99
    CrossrefPubMedGoogle Scholar
  • 7 Zargar A H, Gupta V K, Wani A I et al.. Prevalence of ultrasonography proved polycystic ovaries in North Indian women with type 2 diabetes mellitus.  Reprod Biol Endocrinol. 2005;  3 35-41
    CrossrefPubMedGoogle Scholar
  • 8 Wijeyaratne C N, Balen A H, Barth J H, Belchetz P E. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference?.  Clin Endocrinol (Oxf). 2002;  57 343-350
    CrossrefPubMedGoogle Scholar
  • 9 Charnvises K, Weerakiet S, Tingthanatikul Y, Wansumrith S, Chanprasertyothin S, Rojanasakul A. Acanthosis nigricans: clinical predictor of abnormal glucose tolerance in Asian women with polycystic ovary syndrome.  Gynecol Endocrinol. 2005;  21 161-164
    CrossrefPubMedGoogle Scholar
  • 10 Franks S. Polycystic ovary syndrome.  N Engl J Med. 1995;  333 853-861
    CrossrefPubMedGoogle Scholar
  • 11 Carmina E, Koyama T, Chang L, Stanczyk F Z, Lobo R A. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?.  Am J Obstet Gynecol. 1992;  167 1807-1812
    PubMedGoogle Scholar
  • 12 Zargar A H, Wani A I, Masoodi S R, Laway B A, Bashir M I, Salahuddin M. Epidemiologic and etiologic aspects of hirsutism in Kashmiri women in the Indian subcontinent.  Fertil Steril. 2002;  77 674-678
    CrossrefPubMedGoogle Scholar
  • 13 Bigazzi R, Bianchi S. Insulin resistance, metabolic syndrome and endothelial dysfunction.  J Nephrol. 2007;  20 10-14
    PubMedGoogle Scholar
  • 14 Vignesh J P, Mohan V. Polycystic ovary syndrome: a component of metabolic syndrome?.  J Postgrad Med. 2007;  53 128-134
    PubMedGoogle Scholar
  • 15 Jialal I, Naiker P, Reddi K, Moodley J, Joubert S M. Evidence for insulin resistance in nonobese patients with polycystic ovarian disease.  J Clin Endocrinol Metab. 1987;  64 1066-1069
    PubMedGoogle Scholar
  • 16 Sundararaman P G, Manomani R, Sridhar G R, Sridhar V, Sundaravalli A, Umachander M. Risk of atherosclerosis in women with polycystic ovary syndrome: a study from South India.  Metabolic Syndrome and Related Disorders.. 2003;  1 271-275
    CrossrefPubMedGoogle Scholar
  • 17 Kaushal R, Parchure N, Bano G, Kaski J C, Nussey S S. Insulin resistance and endothelial dysfunction in the brothers of Indian subcontinent Asian women with polycystic ovaries.  Clin Endocrinol (Oxf). 2004;  60 322-328
    CrossrefPubMedGoogle Scholar
  • 18 Deedwania P C, Gupta R. Management issues in the metabolic syndrome.  J Assoc Physicians India. 2006;  54 797-810
    PubMedGoogle Scholar
  • 19 Yoon K H, Lee J H, Kim J W et al.. Epidemic obesity and type 2 diabetes in Asia.  Lancet. 2006;  368 1681-1688
    CrossrefPubMedGoogle Scholar
  • 20 Gupta A, Gupta R, Sarna M, Rastogi S, Gupta V P, Kothari K. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population.  Diabetes Res Clin Pract. 2003;  61 69-76
    CrossrefPubMedGoogle Scholar
  • 21 Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.  J Clin Endocrinol Metab. 1999;  84 165-169
    CrossrefPubMedGoogle Scholar
  • 22 Weerakiet S, Srisombut C, Rojanasakul A, Panburana P, Thakkinstian A, Herabutya Y. Prevalence of gestational diabetes mellitus and pregnancy outcomes in Asian women with polycystic ovary syndrome.  Gynecol Endocrinol. 2004;  19 134-140
    CrossrefPubMedGoogle Scholar
  • 23 Park K H, Kim J Y, Ahn C W, Song Y D, Lim S K, Lee H C. Polycystic ovarian syndrome (PCOS) and insulin resistance.  Int J Gynaecol Obstet. 2001;  74 261-267
    CrossrefPubMedGoogle Scholar
  • 24 Ek I, Arner P, Bergqvist A, Carlstrom K, Wahrenberg H. Impaired adipocyte lipolysis in nonobese women with the polycystic ovary syndrome: a possible link to insulin resistance?.  J Clin Endocrinol Metab. 1997;  82 1147-1153
    CrossrefPubMedGoogle Scholar
  • 25 Norman R J, Masters L, Milner C R, Wang X J, Davies M J. Relative risk of conversion from normoglycemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.  Hum Reprod. 2001;  16 1995-1998
    CrossrefPubMedGoogle Scholar
  • 26 Borch-Johnsen K. The metabolic syndrome in a global perspective. The public health impact-secondary publication.  Dan Med Bull. 2007;  54 157-159
    PubMedGoogle Scholar
  • 27 Zeyneloglu H B, Esinler I. Chronic complications of polycystic ovary syndrome. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 102-112
    Google Scholar
  • 28 Apridonidze T, Essah P A, Iuorno M J, Nestler J E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2005;  90 1929-1935
    CrossrefPubMedGoogle Scholar
  • 29 Wijeyaratne C N, Waduge R, Arandara D et al.. Metabolic and polycystic ovary syndromes in indigenous South Asian women with previous gestational diabetes mellitus.  BJOG. 2006;  113 1182-1187
    PubMedGoogle Scholar
  • 30 Kousta E, Cela E, Lawrence N et al.. The prevalence of polycystic ovaries in women with a history of gestational diabetes.  Clin Endocrinol (Oxf). 2000;  53 501-507
    CrossrefPubMedGoogle Scholar
  • 31 Solomon C G, Hu F B, Dunaif A et al.. Menstrual cycle irregularity and risk for future cardiovascular disease.  J Clin Endocrinol Metab. 2002;  87 2013-2017
    CrossrefPubMedGoogle Scholar
  • 32 Wijeyaratne C N, Nirantharakumar K, Balen A H, Barth J H, Sheriff R, Belchetz P E. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity?.  Clin Endocrinol (Oxf). 2004;  60 560-567
    CrossrefPubMedGoogle Scholar
  • 33 Escobar-Morreale H F, Luque-Ramírez M, San Millán J L. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome.  Endocr Rev. 2005;  26 251-282
    CrossrefPubMedGoogle Scholar
  • 34 Crosignani P G, Nicolosi A E. Polycystic ovarian disease: heritability and heterogeneity.  Hum Reprod Update. 2001;  7 3-7
    CrossrefPubMedGoogle Scholar
  • 35 Babu K A, Rao K L, Kanakavalli M K, Suryanarayana V V, Deenadayal M, Singh L. CYP1A1, GSTM1 and GSTT1 genetic polymorphism is associated with susceptibility to polycystic ovaries in South Indian women.  Reprod Biomed Online. 2004;  9 194-200
    PubMedGoogle Scholar
  • 36 Pasquali R, Casimirri F. The impact of obesity in hyperandrogenism and polycystic ovary syndrome in premenopausal women.  Clin Endocrinol (Oxf). 1993;  39 1-16
    CrossrefPubMedGoogle Scholar
  • 37 Hartz A J, Barboriak P N, Wong A, Katayama K P, Rimm A A. The association of obesity with infertility and related menstural abnormalities in women.  Int J Obes. 1979;  3 57-73
    PubMedGoogle Scholar
  • 38 Chang R J, Nakamura R M, Judd H L, Kaplan S A. Insulin resistance in nonobese patients with polycystic ovarian disease.  J Clin Endocrinol Metab. 1983;  57 356-359
    CrossrefPubMedGoogle Scholar
  • 39 ESHRE/ASRM . ESHRE/ASRM Rotterdam Consensus Meeting Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).  Hum Reprod. 2004;  19 41-47
    CrossrefPubMedGoogle Scholar
  • 40 Ajayi R, Ogunmokun A. The importance of diagnosing polycystic ovary syndrome. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 38-45
    Google Scholar
  • 41 Atabekoglu C S, Arici A. Pharmacologic treatment of polycystic ovary syndrome in the reproductive years. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 246-268
    Google Scholar
  • 42 Wiegratz I, Kutschera E, Lee J H et al.. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins.  Contraception. 2003;  67 361-366
    CrossrefPubMedGoogle Scholar
  • 43 Guido M, Romualdi D, Giuliani M et al.. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.  J Clin Endocrinol Metab. 2004;  89 2817-2823
    CrossrefPubMedGoogle Scholar
  • 44 Rosen M P, Breitkopf D M, Nagamani M. A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris.  Am J Obstet Gynecol. 2003;  188 1158-1160
    CrossrefPubMedGoogle Scholar
  • 45 Farquhar C, Lee O, Toomath R, Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.  Cochrane Database Syst Rev. 2003;  4 CD000194
    PubMedGoogle Scholar
  • 46 Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.  J Clin Endocrinol Metab. 2003;  88 4116-4123
    CrossrefPubMedGoogle Scholar
  • 47 Morin-Papunen L C, Koivunen R M, Ruokonen A, Martikainem H K. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.  Fertil Steril. 1998;  69 691-696
    CrossrefPubMedGoogle Scholar
  • 48 Allahbadia G N, Agrawal R. Clomiphene citrate for ovulation induction in women with polycystic ovary syndrome. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 357-365
    Google Scholar
  • 49 ESHRE Capri Workshop Group . Monoovulatory cycles: a key goal in profertility programmes.  Hum Reprod Update. 2003;  9 263-274
    CrossrefPubMedGoogle Scholar
  • 50 Branigan E F, Estes M A. Treatment of chronic anovulation resistant to clomiphene citrate (CC) by using oral contraceptive ovarian suppression followed by repeat CC treatment.  Fertil Steril. 1999;  71 544-546
    CrossrefPubMedGoogle Scholar
  • 51 Mitwally M FM, Casper R F. The development, mechanism of action and use of aromatase inhibitors for ovulation induction in polycystic ovary syndrome. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 346-356
    Google Scholar
  • 52 Fleming R, Sattar N. Should patients with polycystic ovary syndrome be treated with metformin?. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 277-289
    Google Scholar
  • 53 Knowler W C, Barrett-Connor E, Fowler S E et al.. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
    CrossrefPubMedGoogle Scholar
  • 54 Ayup S H, Vega P G, Halliscak R S et al.. Insulin-sensitizing drugs in the treatment of women with PCOS - the promise of metformin. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 297-305
    Google Scholar
  • 55 Kriplani A, Agarwal N. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.  J Reprod Med. 2004;  49 361-367
    PubMedGoogle Scholar
  • 56 Harborne L R, Sattar N, Norman J E, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses.  J Clin Endocrinol Metab. 2005;  90 4593-4598
    CrossrefPubMedGoogle Scholar
  • 57 Lord J M, Flight I H, Norman R J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis.  BMJ. 2003;  327 951-953
    PubMedGoogle Scholar
  • 58 Palomba S, Orio Jr F, Falbo A et al.. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2005;  90 4068-4074
    CrossrefPubMedGoogle Scholar
  • 59 De Leo V, Marca A, Ditto A, Morgante G, Cionci A. Effects of metformin on gonadotropin-induced ovulation in women with PCOS.  Fertil Steril. 1999;  72 282-285
    CrossrefPubMedGoogle Scholar
  • 60 Yarali H, Yildiz B O, Demirol A et al.. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial.  Hum Reprod. 2002;  17 289-294
    CrossrefPubMedGoogle Scholar
  • 61 Christin-Maitre S, Hugues J N. Recombinant FSH Study Group. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome.  Hum Reprod. 2003;  18 1626-1631
    CrossrefPubMedGoogle Scholar
  • 62 Homburg R, Levy T, Berkovitz D. Gonadotropin releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome.  Fertil Steril. 1993;  59 527-531
    PubMedGoogle Scholar
  • 63 Asia Pacific Cohort Studies Collaboration . The burden of overweight and obesity in the Asia-Pacific region.  Obes Rev. 2007;  8 191-196
    CrossrefPubMedGoogle Scholar
  • 64 Palep-Singh M, Picton H M, Vrotsou K, Maruthini D, Balen A H. South Asian women with polycystic ovary syndrome exhibit greater sensitivity to gonadotropin stimulation with reduced fertilization and ongoing pregnancy rates than their Caucasian counterparts.  Eur J Obstet Gynecol Reprod Biol. 2007;  134 202-207
    CrossrefPubMedGoogle Scholar
  • 65 Xita N, Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies.  J Clin Endocrinol Metab. 2006;  91 1660-1666
    CrossrefPubMedGoogle Scholar
  • 66 Tuomilehto J, Lindstrom J, Eriksson J G et al.. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
    CrossrefPubMedGoogle Scholar
  • 67 Kiddy D S, Hamilton-Fairley D, Bush A et al.. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome.  Clin Endocrinol (Oxf). 1992;  36 105-111
    CrossrefPubMedGoogle Scholar
  • 68 Piacquadio D J, Rad F S, Spellman M C, Hollenbach K A. Obesity and female androgenic alopecia: a cause and an effect?.  J Am Acad Dermatol. 1994;  30 1028-1030
    PubMedGoogle Scholar
  • 69 Clark A M, Thornley B, Tomlinson L, Galletley C, Norman R J. Weight loss in obese infertile women 0results in improvement in reproductive outcome for all forms of fertility treatment.  Hum Reprod. 1998;  13 1502-1505
    CrossrefPubMedGoogle Scholar
  • 70 Daskalopoulou S S, Mikhailidis D P, Elisaf M. Prevention and treatment of the metabolic syndrome.  Angiology. 2004;  55 589-612
    PubMedGoogle Scholar
  • 71 Poongothai S, Karkuzhali K, Sharadha J, Deepa R, Mohan V. Evaluation of safety and efficacy of Hyponidd, an Ayurvedic compound: a double blind, placebo controlled study in type 2 diabetic patients with secondary failure to oral drugs.  Int J Diab Dev Ctries. 2002;  22 19-27
    PubMedGoogle Scholar
  • 72 Stanley P, Prince M, Menon V P. Hypoglycaemic and other related actions of Tinospora cordifolia roots in alloxan-induced diabetic rats.  J Ethnopharmacol. 2000;  70 9-15
    CrossrefPubMedGoogle Scholar
  • 73 Shanmugasundaram E R, Rajeswari G, Baskaran K et al.. Use of Gymnema Sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus.  J Ethnopharmacol. 1990;  30 281-294
    CrossrefPubMedGoogle Scholar
  • 74 Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K, Shanmugasundaram E R. Antidiabetic effect of a leaf extract from Gymnema Sylvestre in non-insulin-dependent diabetes mellitus patients.  J Ethnopharmacol. 1990;  30 295-300
    CrossrefPubMedGoogle Scholar
  • 75 Persaud S J, Al-Majed H, Raman A, Jones P M. Gymnema Sylvestre stimulates insulin release in vitro by increased membrane permeability.  J Endocrinol. 1999;  163 207-212
    CrossrefPubMedGoogle Scholar
  • 76 Indian Council of Medical Research (ICMR) Collaboration Centre . Flexible dose open trial of Vijayasar in cases of newly-diagnosed non-insulin-dependent diabetes mellitus.  Indian J Med Res. 1998;  108 24-29
    PubMedGoogle Scholar
  • 77 Lodha R, Bagga A. Traditional Indian systems of medicine.  Ann Acad Med Singapore. 2000;  29 37-41
    PubMedGoogle Scholar
  • 78 Leatherdale B A, Panesar R K, Singh G, Atkins T W, Bailey C J, Bignell A H. Improvement in glucose tolerance due to Momordica charantia (Karela).  Br Med J (Clin Res Ed). 1981;  282 1823-1824
    CrossrefPubMedGoogle Scholar
  • 79 Kedar P, Chakrabarti C H. Effects of Jambolan seed treatment on blood sugar, lipids and urea on steptozocin induced diabetes in rabbits.  Indian J Physiol Pharmacol. 1983;  27 135-140
    PubMedGoogle Scholar
  • 80 Bopanna K N, Kannan J, Gadgil S, Balraman R, Rathod S P. Antidiabetic and antihyperlipaemic effects of neem seed kernel powder on alloxan diabetic rabbits.  Indian J Pharmacol. 1997;  29 162-167
    PubMedGoogle Scholar
  • 81 Babu P S, Stanely Mainzen Prince P. Antihyperglycaemic and antioxidant effect of hyponidd, an ayurvedic herbomineral formulation in streptozotocin-induced diabetic rats.  J Pharm Pharmacol. 2004;  56 1435-1442
    CrossrefPubMedGoogle Scholar
  • 82 Seshaiah V, Sundaram A, Balaji V, Moses A. Role of Hyponidd in the treatment of noninsulin dependent diabetes mellitus.  Indian Journal of Clinical Practice. 1998;  8 1-5
    PubMedGoogle Scholar
  • 83 Allahbadia G N, Kadam K S, Gandhi G N, Arora S, Virk S, Kaur K. To study the efficacy and tolerability of a traditional Indian drug containing D-chiro-inositol versus metformin in hyperinsulinemic PCOS subjects.  Fertil Steril. 2006;  86 S461
    PubMedGoogle Scholar
  • 84 Sheikhha M H, Kalantar S M. Diagnostic criteria in polycystic ovary syndrome. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 27-32
    Google Scholar
  • 85 Fleming R, Harborne L, MacLaughlin D T et al.. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment.  Fertil Steril. 2005;  83 130-136
    CrossrefPubMedGoogle Scholar
  • 86 Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome.  BJOG. 2006;  113 1148-1159
    CrossrefPubMedGoogle Scholar
  • 87 Misra A, Misra R, Wijesuriya M, Banerjee D. The metabolic syndrome in South Asians: continuing escalation & possible solutions.  Indian J Med Res. 2007;  125 345-354
    PubMedGoogle Scholar
  • 88 Vikram N K, Misra A, Pandey R M et al.. Anthropometry and body composition in northern Asian Indian patients with type 2 diabetes: receiver operating characteristics (ROC) curve analysis of body mass index with percentage body fat as standard.  Diabetes Nutr Metab. 2003;  16 32-40
    PubMedGoogle Scholar

Gautam N AllahbadiaM.D. 

Medical Director, Rotunda - The Center For Human Reproduction

672, Kalpak Gulistan, Perry Cross Road, Near Otter's Club, Bandra (W) 400 050, India

Email: drallah@gmail.com

      >